Replimune (REPL) Prices 2.826M Share Common Offering at $23/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Replimune Announces Pricing of Upsized Public Offering
June 8, 2020 11:20 PM EDTBOSTON, June 08, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced the pricing of its public offering of 2,826,088 shares of its common stock at a public offering price of $23.00 per share. In addition, in lieu of common stock to certain investors, Replimune today announced the pricing of its public offering of pre-funded warrants to purchase 1,521,738 shares of its common stock at a purchase price of $22.9999 per pre-funded warrant, which equals the public offering price per share of the common... More



